Predictive value of brain tumor reporting and data system scores for functional outcomes and progression-free survival in glioblastoma [0.03%]
胶质母细胞瘤脑肿瘤报告和数据系统评分对功能预后及无进展生存期的预测价值
Michele Persico,Michael Essien,Tsion Assaye et al.
Michele Persico et al.
Background: The Brain Tumor Reporting and Data System (BT-RADS) is a standardized reporting system developed for routine clinical use for MRI interpretation in patients with primary brain tumors. This study evaluates the ...
H3K27M-altered diffuse midline glioma: Experience and outcomes from a low-middle income country setting in the contemporary era [0.03%]
当代低中等收入国家H3K27M改变的弥漫性中线胶质瘤的诊疗经验及预后
Meenakshi Jeeva,Mamta Gurav,Abhishek Chatterjee et al.
Meenakshi Jeeva et al.
Purpose: H3K27M-altered diffuse midline glioma (DMG) is an aggressive pediatric-type high-grade glioma (HGG) arising from midline structures in the central nervous system. This report summarizes the experience with this d...
Targeting immune microenvironment-mediated mesenchymal transition in glioblastoma: Molecular mechanisms and translational strategies [0.03%]
针对胶质母细胞瘤免疫微环境介导的间充质转化：分子机制和转化策略
Fengye Liu,Junyi Chen,Muying Yu et al.
Fengye Liu et al.
Glioblastoma remains uniformly lethal due to profound phenotypic plasticity and adaptive resistance. The proneural-to-mesenchymal transition (PMT) has emerged as a central axis functionally linking immune evasion, metabolic rewiring, and li...
Real-world mortality and the effect of comorbidities on survival in glioblastoma: A database study using computed phenotypes for rapid, reliable patient identification [0.03%]
胶质母细胞瘤真实世界的死亡率及合并症对生存期的影响：使用计算机表型进行快速可靠患者识别的数据库研究
Ruoqi Wei,Megan E H Still,Rachel S F Moor et al.
Ruoqi Wei et al.
Introduction: Glioblastoma (GBM) continues to have poor prognosis with minimal improvement since the introduction of the Stupp protocol. While clinical data are often homogenous and not generalizable, real-world data can ...
Cerebrospinal fluid soluble protein tyrosine phosphatase receptor type Z detected with human natural killer-1 antibody as a practical biomarker for glioma diagnosis [0.03%]
人天然杀伤细胞-1抗体检测脑脊液中可溶性蛋白质酪氨酸磷酸酶受体类型Z作为胶质瘤诊断的实用生物标志物
Yu Naruse,Masazumi Fujii,Kenichiro Nagai et al.
Yu Naruse et al.
Background: A major challenge in managing gliomas is the lack of reliable and clinically applicable biomarkers. Imaging alone is often insufficient to distinguish gliomas from primary central nervous system lymphoma (PCNS...
Enhancing cognitive accessibility in existential -psychotherapy for adults with brain tumors: A patient-informed approach to intervention adaptation [0.03%]
基于患者的成人脑肿瘤存在主义心理治疗认知可及性增强法：干预适应方法
Ashlee R Loughan,Autumn Lanoye,Alex Davies et al.
Ashlee R Loughan et al.
Individuals with primary or secondary brain tumors experience double vulnerability-significant emotional distress alongside cognitive decline. These cognitive changes often prohibit their inclusion in psychotherapeutic interventions due to ...
A methylome-based score to predict survival after regorafenib in recurrent glioblastoma [0.03%]
基于甲基化谱的雷戈菲尼预后评估模型在复发胶质母细胞瘤中的预测作用
Silvia Chiesa,Evelina Miele,Sara Patrizi et al.
Silvia Chiesa et al.
Background: Following the encouraging results of the REGOMA Phase 2 trial, regorafenib is increasingly used for the treatment of recurrent glioblastoma, IDH-wildtype. Identifying predictive factors for response to regoraf...
High-resolution thermal imaging to delineate effects of cancer-induced aerobic glycolysis and endothelial dysfunction [0.03%]
高分辨率热成像鉴别癌症诱导有氧糖酵解和内皮细胞功能障碍的作用效应
Daniel Coman,Peter Herman,Jyotsna U Rao et al.
Daniel Coman et al.
Background: Glioblastoma multiforme (GBM) is an aggressive brain tumor with abysmal prognosis because cancer cell growth in the tumor microenvironment (TME) is orchestrated by complex interplay between aerobic glycolysis ...
Boron neutron capture therapy plus bevacizumab versus bevacizumab alone in recurrent glioblastoma: A propensity score-matched analysis [0.03%]
硼中子俘获治疗联合贝伐单抗与单纯贝伐单抗治疗复发性胶质母细胞瘤的倾向性匹配分析
Shuo-Fu Chen,Yi-Yen Lee,Chun-Yu Liu et al.
Shuo-Fu Chen et al.
Background: Boron neutron capture therapy (BNCT) presents a targeted re-irradiation strategy for recurrent glioblastoma. However, its survival benefit remains unclear, as few studies have compared the addition of BNCT to ...
The future of targeted therapies for pediatric central nervous system tumors [0.03%]
儿童中枢神经系统肿瘤靶向治疗的未来方向
Holly Lindsay,Eric Bouffet
Holly Lindsay
Targeted therapies are changing the landscape of pediatric brain tumor management. They offer the opportunity of more effective and personalized treatment strategies, with reduced side effects and improved outcomes. This paradigm shift in p...